NKTR-214 with Opdivo Earns FDA’s Breakthrough Therapy Designation for Advanced Melanoma

Source: Immuno-oncology, October 2019

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for a combination of the potential therapy NKTR-214 with Opdivo (nivolumab) for untreated melanoma patients with either metastatic disease or who are unable to undergo surgery.

A global Phase 3 clinical trial (NCT03635983) comparing the effectiveness and safety of add-on NKTR-214 to Opdivo alone in first-line treatment of advanced melanoma patients is currently enrolling. More information on contacts, open locations and those yet to open can be found here.

NKTR-214, or bempegaldesleukin, is Nektar Therapeutics’ lead immuno-oncology candidate. It works by promoting the activation and proliferation of a subset of immune T-cells and natural killer (NK) cells, both capable of eliminating cancer cells.

Read the original full article

2019 Events

Calculate your risk of getting melanoma Sunscreen calculator
Map of body for recording areas of skin causing you concern on your body Target Therapy Finder